Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019062949) COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/062949 International Application No.: PCT/CN2018/108762
Publication Date: 04.04.2019 International Filing Date: 29.09.2018
IPC:
C07D 403/14 (2006.01) ,C07D 401/14 (2006.01) ,A61K 31/506 (2006.01) ,A61K 31/404 (2006.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14
containing three or more hetero rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506
not condensed and containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
40
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403
condensed with carbocyclic rings, e.g. carbazole
404
Indoles, e.g. pindolol
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
上海海和药物研究开发有限公司 SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. [CN/CN]; 中国上海市 中国(上海)自由贸易试验区牛顿路421号6幢103部位208室 Rm. 208, Section 103, Building 6, No. 421, Newton Rd., China (Shanghai) Pilot Free Trade Zone Shanghai 201203, CN
中国科学院上海药物研究所 SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES [CN/CN]; 中国上海市 浦东张江祖冲之路555号 555 Zuchongzhi Road, Zhangjiang, Pudong Shanghai 201203, CN
Inventors:
李磊 LI, Lei; CN
耿美玉 GENG, Meiyu; CN
黄颖 HUANG, Ying; CN
丁健 DING, Jian; CN
张琼 ZHANG, Qiong; CN
黄敏 HUANG, Min; CN
唐帅 TANG, Shuai; CN
沈宁 SHEN, Ning; CN
陈奕 CHEN, Yi; CN
Agent:
北京市中咨律师事务所 ZHONGZI LAW OFFICE; 中国北京市 西城区平安里西大街26号新时代大厦7层 7F, New Era Building, 26 Pinganli Xidajie, Xicheng District Beijing 100034, CN
Priority Data:
201710915493.530.09.2017CN
Title (EN) COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF
(FR) COMPOSÉ PRÉSENTANT UNE ACTIVITÉ INHIBITRICE DE KINASE ERK ET SON UTILISATION
(ZH) 具有ERK激酶抑制活性的化合物及其用途
Abstract:
(EN) A compound represented by formula (I). Variables in the compound represented by formula (I) are as defined in the specification. The compound is an inhibitor of an ERK kinase, e.g., ERK1 and/or ERK2. Also provided are a use of and a preparation method for the compound, and a pharmaceutical composition containing the compound.
(FR) L'invention porte sur un composé représenté par la formule (I). Les variables du composé représenté par la formule (I) sont telles que définies dans la description. Le composé est un inhibiteur d'une kinase ERK, par exemple ERK1 et/ou ERK2. L'invention concerne également un procédé d'utilisation et de préparation du composé, et une composition pharmaceutique contenant le composé.
(ZH) 一种式(I)的化合物。其中各变量如说明书中所定义。所述化合物是ERK激酶、例如ERK1和/或ERK2激酶的抑制剂。还涉及所述化合物的用途和制备方法以及包含所述化合物的药物组合物。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)